期刊
ANNUAL REVIEW OF MEDICINE, VOL 64
卷 64, 期 -, 页码 407-425出版社
ANNUAL REVIEWS
DOI: 10.1146/annurev-med-120611-144851
关键词
nonsense codons; premature translation termination; inherited disorders; nonsense codon readthrough; PTC124/ataluren
资金
- NIGMS NIH HHS [R01 GM027757, R37 GM27757, R37 GM027757] Funding Source: Medline
- NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027757, R37GM027757] Funding Source: NIH RePORTER
The interplay of translation and mRNA turnover has helped unveil how the regulation of gene expression is a continuum in which events that occur during the birth of a transcript in the nucleus can have profound effects on subsequent steps in the cytoplasm. Exemplifying this continuum is nonsense-mediated mRNA decay (NMD), the process wherein a premature stop codon affects both translation and mRNA decay. Studies of NMD helped lead us to the therapeutic concept of treating a subset of patients suffering from multiple genetic disorders due to nonsense mutations with a single small-molecule drug that modulates the translation termination process at a premature nonsense codon. Here we review both translation termination and NMD, and our subsequent efforts over the past 15 years that led to the identification, characterization, and clinical testing of ataluren, a new therapeutic with the potential to treat a broad range of genetic disorders due to nonsense mutations.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据